1. Scrip
  2. >>Business
  3. >>Deals

Viventia's Cancer Ambitions Go To Eleven

 
• By Joseph Haas

Merger with troubled ophthalmology biotech Eleven takes Viventia public and joins the protein-engineering and manufacturing expertise of the two firms. Lead candidate Vicinium is in Phase III for high-grade, non-muscle invasive bladder cancer.

US dollars and pills

Eleven Biotherapeutics Inc. will live on, at least in name, following a merger with Canada's Viventia Bio Inc., resulting in a new company named Eleven that will focus primarily on Viventia's legacy Phase III targeted protein therapeutic Vicinium for bladder cancer and Phase II-ready Proxinium for head-and-neck cancer.

On Sept. 21, the two companies announced the transaction, effective immediately, in which Eleven purchased all outstanding shares in Viventia in exchange for the issuance of 4m-plus shares of Eleven common stock

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.